Key result
Concomitant administration of monovalent, bivalent, or trivalent OPV with RV1 lowered rotavirus seroconversion compared to staggered administration.
Why the study?
Does concomitant administration of OPV reduce RV1 immunogenicity in healthy infants compared to staggered administration?
RCT (n=409)
randomized
No
Does concomitant administration of OPV reduce RV1 immunogenicity in healthy infants compared to staggered administration?
Answers are grounded in this paper and cite their sources.
Coadministration of OPV and RV1 on the same day significantly lowers rotavirus vaccine immunogenicity compared to staggered administration.
BACKGROUND: Trivalent oral poliovirus vaccine (OPV) is known to interfere with monovalent rotavirus vaccine (RV1) immunogenicity. The interference caused by bivalent and monovalent OPV formulations, which will be increasingly used globally in coming years, has not been examined. We conducted a post hoc analysis to assess the effect of coadministration of different OPV formulations on RV1 immunogenicity. METHODS: Healthy infants in Matlab, Bangladesh, were randomized to receive 3 doses of monovalent OPV type 1 or bivalent OPV types 1 and 3 at either 6, 8, and 10 or 6, 10, and 14 weeks of age or trivalent OPV at 6, 10, and 14 weeks of age. All infants received 2 doses of RV1 at about 6 and 10 weeks of age. Concomitant administration was defined as RV1 and OPV given on the same day; staggered administration as RV1 and OPV given ≥1 day apart. Rotavirus seroconversion was defined as a 4-fold rise in immunoglobulin A titer from before the first RV1 dose to ≥3 weeks after the second RV1 dose. RESULTS: There were no significant differences in baseline RV1 immunogenicity among the 409 infants included in the final analysis. Infants who received RV1 and OPV concomitantly, regardless of OPV formulation, were less likely to seroconvert (47%; 95% confidence interval, 39%-54%) than those who received both vaccines staggered ≥1 day (63%; 57%-70%; P < .001). For staggered administration, we found no evidence that the interval between RV1 and OPV administration affected RV1 immunogenicity. CONCLUSIONS: Coadministration of monovalent, bivalent, or trivalent OPV seems to lower RV1 immunogenicity. CLINICAL TRIALS REGISTRATION: NCT01633216.
No takes yet. Share an insight, caveat, or question.
Emperador et al. (2015) conducted an RCT in Healthy infants (n=409). Concomitant administration of RV1 and OPV vs. Staggered administration of RV1 and OPV (≥1 day apart) was evaluated on Rotavirus seroconversion (4-fold rise in immunoglobulin A titer) (p=< .001). Concomitant administration of monovalent, bivalent, or trivalent OPV with RV1 lowered rotavirus seroconversion compared to staggered administration.
Synapse has enriched 10 related papers. Consider them for comparative context: